Biomarker Discovery for Sepsis Research
From Data to Phase 2 Trials: 9 Validated Biomarkers in 30 Days
The Challenge
A pharmaceutical partner needed to identify biomarkers indicating the onset of septic shock with vascular leakage. Their therapeutic had a narrow administration window—too early was ineffective, too late was dangerous.
Traditional biomarker discovery timelines of 6-12 months were unacceptable. The research team needed validated targets in weeks, not months.
The Approach
BioInfo AI deployed a multi-agent pipeline using our Validated Agent Development Framework:
Data Ingestion Agents
Cleansed and normalized genomic expression data from multiple sources
Correlation Agents
Identified statistical relationships across millions of expression measurements
Staging Agents
Prepared data for rapid scientific analysis
Visualization Agents
Generated network diagrams for researcher interpretation
Our CSO directed the scientific analysis while AI agents handled data preparation at a pace impossible for manual processing.
The Results
All 9 biomarkers passed the pharmaceutical partner's internal validation process on the first submission—an unprecedented success rate. Those biomarkers have now progressed to Phase 2 clinical trials with actual patients.
The Impact
The 30-day timeline from project kickoff to validated targets demonstrated that AI-augmented biomarker discovery can dramatically accelerate pharmaceutical research without sacrificing scientific rigor.
This engagement validated our Validated Agent Development Framework in a high-stakes pharmaceutical context—and established BioInfo AI as a trusted partner for biomarker discovery.
Ready for Similar Results?
Let's discuss how our approach could accelerate your research program.